| Identification | Back Directory | [Name]
10H,18H-4,1-([4,3]-endo-Pyrazolomethanothiomethano[3,5]-endo-pyrazoloethano[3,1]naphthalenoxypropano)-1H-indole-2-carboxylic acid, 5-chloro-28-fluoro-10-[2-(2-methoxyethoxy)ethyl]-3,12,18-trimethyl-, (4S)- | [CAS]
2697112-33-5 | [Synonyms]
10H,18H-4,1-([4,3]-endo-Pyrazolomethanothiomethano[3,5]-endo-pyrazoloethano[3,1]naphthalenoxypropano)-1H-indole-2-carboxylic acid, 5-chloro-28-fluoro-10-[2-(2-methoxyethoxy)ethyl]-3,12,18-trimethyl-, (4S)- | [Molecular Formula]
C40H43ClFN5O5S | [MOL File]
2697112-33-5.mol | [Molecular Weight]
760.32 |
| Hazard Information | Back Directory | [Uses]
JNJ-4355 is a highly potent MCL-1 (myeloid cell leukemia-1) inhibitor, with KI of 18 pM. JNJ-4355 shows antitumor activity[1][2]. | [in vivo]
JNJ-4355 (IV , single) shows complete tumor regression in a mouse MOLP8 (multiple myeloma) xenograft[2]. | [IC 50]
Mcl-1: 18 pM (Ki) | [References]
[1] Matthieu Jouffroy, et al. Synthesis of Atropisomeric Biaryls via Chiral Suzuki–Miyaura/Enzymatic Kinetic Resolution. ACS Catal. 2022, 12, 8380–8385.
[2] Frederik J. Rombouts, et al. Abstract 2133: In pursuit of MCL-1 inhibitors with improved therapeutic window for the treatment of hematological malignancies: Discovery of JNJ-4355. Cancer Res (2022) 82 (12_Supplement): 2133. |
|
|